Graham Dixon, PhD, chief scientific officer, Onxeo, discusses a mechanistic study of the relative cytotoxicity of doxorubicin-loaded nanoparticle formulation versus doxorubicin in hepatocellular carcinoma (HCC) cell lines.

The agent is currently being investigated in comparison with best standard of care in the phase III Relive trial, Dixon explains. As of March 2016, 65% of the 400 patients have been randomized. Preliminary results will be available in 2017, he adds.

The doxorubicin-loaded nanoparticle formulation has been targeted for the second-line setting for patients with HCC. Key findings from the mechanistic study demonstrate how the nanoparticle directly targets the liver. Secondly, the mechanism of action of this agent is unique, Dixon adds, in that it evades the efflux pumps that are present in HCC cells, allowing for higher concentration and delivery of cytotoxic action. 

Videos

Graham Dixon, PhD, chief scientific officer, Onxeo, discusses a mechanistic study of the relative cytotoxicity of doxorubicin-loaded nanoparticle formulation versus doxorubicin in hepatocellular carcinoma cell lines. 


Doxorubicin-Loaded Nanoparticle Formulation in Patients With HCC

Graham Dixon, PhD, chief scientific officer, director of R&D, Onxeo, discusses a phase I study investigating the combination of belinostat (Beleodaq) plus CHOP in patients with peripheral T-cell lymphoma.

Belinostat is an HDAC inhibitor that was well tolerated in patients with peripheral T-cell lymphoma in the open-label, two-part study, Dixon explains, especially when combined with CHOP in the first-line setting. In this study, complete responses were reported in 67% of patients who received the combination. The overall response rate was 86%. 

Dixon hopes additional studies will reflect these findings and lead to an expanded approval of belinostat in the first-line setting. The agent is currently approved by the FDA as a second-line treatment of relapsed/refractory peripheral T-cell lymphoma. 

Graham Dixon, PhD, chief scientific officer, Onxeo, director, R&D, Onxeo, discusses a phase I study investigating the combination of belinostat (Beleodaq) plus CHOP in patients with peripheral T-cell lymphoma. 

Graham Dixon, PhD

Articles

Doxorubicin-Loaded Nanoparticle Formulation in Patients With HCC

Graham Dixon on Belinostat Plus CHOP in Patients With T-Cell Lymphoma